Business
PHBI Pharmagreen Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch
PHBI Pharmagreen Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch.
About this update from Pharmagreen Biotech Inc.
[{"type":"text","content":"\n CARSON CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Pharmagreen Biotech, Inc., (OTCQB: PHBI), (“Pharmagreen” or the “Company” is pleased to announce that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain β-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. The company has also updated its corporate website www.pharmagreen.ca with latest business development. The nutraceutical market was worth around USD $449.5 Billion in 2021 and is estimated to grow to about USD $745.5 billion by 2028. As per the analysis shared by Zion market research report, the Nutraceutical Market is expected to grow annually at a CAGR of around 8% (2022-2028). Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions. As stated in the previous news release, Pharmagreen is contin...